Anandron

• Androgen Antagonists
• Antineoplastic Agents
• ATC:L02BB02

• Anandron
• Nilandron
• Nilandrone
• Nilutamida [Spanish]
• Nilutamide [Usan:Ban:Inn]
• Nilutamidum [Latin]

• No information avaliable

C₁₂H₁₀F₃N₃O₄

http://www.rxlist.com/cgi/generic2/nilutam.htm

No information avaliable

317.221 g/mol

No information avaliable

No information avaliable

Solid

2.232

Tablet

For use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2)

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Rapidly and completely absorbed, yielding high and persistent plasma concentrations.

Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.

Patients should be informed that NILANDRON tablets should be started on the day of, or on the day after, surgical castration. They should also be informed that they should not interrupt their dosing of NILANDRON or stop taking this medication without consulting their physician.
Because of the possibility of interstitial pneumonitis, patients should also be told to report immediately any dyspnea or aggravation of pre-existing dyspnea.

Because of the possibility of hepatitis, patients should be told to consult with their physician should nausea, vomiting, abdominal pain, or jaundice occur.
Because of the possibility of an intolerance to alcohol (facial flushes, malaise, hypotension) following ingestion of NILANDRON, it is recommended that intake of alcoholic beverages be avoided by patients who experience this reaction. This effect has been reported in about 5% of patients treated with NILANDRON.

In clinical trials, 13% to 57% of patients receiving NILANDRON reported a delay in adaptation to dark, ranging from seconds to a few minutes, when passing from a lighted area to a dark area. This effect sometimes does not abate as drug treatment is continued. Patients who experience this effect should be cautioned about driving at night or through tunnels. This effect can be alleviated by the wearing of tinted glasses.

Humans and other mammals